Statements (19)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
|
gptkbp:approvalYear |
2022
|
gptkbp:ATCCode |
N07XX18
|
gptkbp:form |
solution for injection
25 mg every 3 months |
gptkbp:genericName |
gptkb:vutrisiran
|
https://www.w3.org/2000/01/rdf-schema#label |
Amvuttra
|
gptkbp:indication |
hereditary transthyretin-mediated amyloidosis
|
gptkbp:legalStatus |
prescription only
|
gptkbp:manufacturer |
gptkb:Alnylam_Pharmaceuticals
|
gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
gptkbp:routeOfAdministration |
subcutaneous injection
|
gptkbp:sideEffect |
injection site reaction
dyspnea arthralgia |
gptkbp:status |
FDA approved
|
gptkbp:target |
gptkb:transthyretin_mRNA
|
gptkbp:bfsParent |
gptkb:Alnylam_Pharmaceuticals
|
gptkbp:bfsLayer |
6
|